

(19)



(11)

EP 1 494 646 B2

(12)

NEW EUROPEAN PATENT SPECIFICATION

After opposition procedure

(45) Date of publication and mention
of the opposition decision:
04.10.2017 Bulletin 2017/40

(45) Mention of the grant of the patent:
11.07.2012 Bulletin 2012/28

(21) Application number: **03744867.7**

(22) Date of filing: **27.03.2003**

(51) Int Cl.:
A61K 9/00 (2006.01)

(86) International application number:
PCT/EP2003/003305

(87) International publication number:
WO 2003/080018 (02.10.2003 Gazette 2003/40)

(54) INTRAVAGINAL MATRIX DRUG DELIVERY DEVICES

INTRAVAGINALE MATRIX-VERABREICHUNGSVORRICHTUNG

DISPOSITIFS D'APPORT PAR VOIE VAGINALE D'UN MEDICAMENT PRESENT DANS UNE
MATRICE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **27.03.2002 IE 20020226**

(43) Date of publication of application:
12.01.2005 Bulletin 2005/02

(73) Proprietor: **Warner Chilcott (Ireland) Limited**
Dundalk
Louth (IE)

(72) Inventors:
• **Muldoon, Brendan**
Belfast BI 10 0JT (GB)

• **Gilligan, Claire**
Belfast BT8 7YP (GB)

(74) Representative: **FRKelly**
27 Clyde Road
Dublin D04 F838 (IE)

(56) References cited:
WO-A-98/50016 WO-A-02/076426
US-A- 4 012 497 US-A- 4 155 991
US-A- 4 292 965 US-A- 5 188 835
US-A- 5 788 980 US-A- 5 855 906
US-A- 5 972 372 US-A- 6 103 256

EP 1 494 646 B2

Description

BACKGROUND OF THE INVENTION

5 FIELD OF THE INVENTION

[0001] This invention is limited to a method according to Claim 1 for altering the release characteristics of intravaginal matrix drug delivery devices. Intravaginal drug delivery devices are designed specifically for intravaginal use and include tablets, pessaries, rod-shapes, ring-shapes and films for adhesion to the mucosal epithelium. Whilst these latter systems can be based on compressed powders, hydrogels, waxes or elastomers, the present invention concerns itself solely with intravaginal matrix drug delivery devices formed from "elastomers", as defined hereinafter.

[0002] Intravaginal elastomer drug delivery devices, designed to deliver steroidal sex hormones, are well known in the art Jackanicz (Jackanicz, T. M., Vaginal Contraception: New Developments. Harper and Row, Hagerstown, pp. 201-212, 1979) teaches that three basic designs of intravaginal elastomer drug delivery device are possible, though additional design variations do exist. The three basic types are the homogeneous design, the shell design and the core design, but the present invention concerns itself solely with the homogeneous or "matrix" design:-

a) The homogeneous or "matrix" design, in which the active (therapeutic) agent (or drug) is homogeneously distributed in an elastomeric system. This design provides for an exponential (first order) release decay, characterised by an initially high release of drug on day 1, known as a "burst" effect followed by a lower maintenance release rate of drug on day 2 and on subsequent days. It is accepted that this design cannot sustain a controlled, substantially constant drug release rate, which will be recognised by those skilled in the art as "zero order release", over a prolonged period.

b) The shell design, in which the active (therapeutic) agent is contained in a narrow band (or annulus) between a non-medicated central elastomeric core and a narrow, outer rate controlling non-medicated elastomeric sheath.

c) The core design, in which the active (therapeutic) agent is homogeneously mixed with an elastomeric polymer to form a homogeneous core, the whole being surrounded by a rate controlling, non-medicated elastomeric sheath.

[0003] United States Patent No 4155991 discloses a composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, consisting essentially of a supporting, medicament-free vaginal ring consisting essentially of a physiologically acceptable synthetic resin and having a continuous encircling pocket-like indentation along the inner edge of the annular surface along the central plane thereof adapted to mate with a corresponding smaller, medicament-containing inner encircling annular minor vaginal ring segment; and a smaller, vaginal medicament-containing inner encircling annular minor vaginal ring adapted to mate with the continuous encircling pocket-like indentation in the modified annular surface of said supporting, medicament-free vaginal ring along the central plane thereof and consisting essentially of a safe and effective amount of a pharmaceutically active nonionic, lipophilic vaginal drug dissolved or uniformly suspended in an elastomeric, crosslinked LTV linear dimethylpolysiloxane resin.

[0004] United States Patent No 5188835 discloses an intravaginal device for use by hypoestrogenic women comprising 17 beta-estradiol incorporated within a supporting elastomeric matrix in such a way that the 17 beta-estradiol will, for at least a month, be continuously released from the elastomeric matrix at an essentially constant rate of about 0.5 to about 25 µg per 24 hours. The described invention also concerns a method of treating hypoestrogenic women by retainably positioning within a woman a medicated intravaginal device, which continuously releases 17β-estradiol at a rate of about 0.5 to about 25 µg/24 h.

[0005] United States Patent No 4012497 discloses a non-toxic sustained release pharmaceutical composition in the form of a shaped object having a Shore A hardness of 45-70, consisting essentially of a safe and pharmaceutically active amount of a nonionic lipophilic drug having a dissociation constant of less than 10⁻⁷ and which is olefinically or acetylenically unsaturated and soluble in ether, chloroform or benzene, said drug being dissolved or uniformly suspended in a non-toxic vulcanized LTV linear dimethylpolysiloxane elastomer and said composition being prepared by reacting, at an elevated temperature and in contact with a catalytic amount of a platinum-based vulcanization catalyst capable of catalyzing the reaction between silicon-linked hydrogen residues and silicon-linked vinyl residues a mixture of said drug and a vulcanizable composition consisting essentially of a polydimethylsiloxane having vinyl groups on both ends; a copolymer consisting essentially of SiO₂ units, (CH₃)₃SiO_{0.5} units, Vinyl (CH₃)₂SiO_{0.5} units; and a cross-linking Si-H component, consisting essentially of (CH₃)₃SiO_{0.5} units, (CH₃)₂SiO units and CH₃HSiO units.

[0006] United States Patent No 6103256 discloses an intravaginal drug delivery device comprising at least one active agent dispersed in a polymer matrix, wherein the concentration of active agent at the outer surface of the device at the time of use is not substantially higher than the concentration of the active agent in the remainder of the device. In particular, it relates to such devices suitable for the administration of a therapeutic agent such as an oestrogen and/or a progestogen, at a substantially constant rate over a prolonged period of time, for example in the treatment of oestrogen

deficiency or in a method of contraception.

[0007] It is an object of the present invention to provide an Intravaginal matrix drug delivery device whose day 1 "burst" effect is adjusted as claimed.

[0008] It is an object of a preferred embodiment of the present invention to provide an intravaginal matrix drug delivery device whose release rate characteristics are substantially independent of shelf life.

[0009] It is a further object of a preferred embodiment of the present invention to enable a therapeutic (active) agent loading, hereinafter referred to as a drug loading, of less than 30% with respect to the total weight of the polymer matrix of at least one therapeutic agent having a solubility in silicone oil at 25°C of less than 0.1mg/ml.

[0010] Accordingly, the present invention provides, in a first aspect a method according to Claim 1 for altering the release characteristics by a process for the preparation of an intravaginal matrix drug delivery device and, in a second aspect, an intravaginal matrix drug delivery device so prepared.

SUMMARY OF THE INVENTION

[0011] This invention is directed to a method for altering the release characteristics by a process for the preparation of an intravaginal matrix drug delivery device, the process comprising the steps defined in Claim 1.

[0012] The selection of a drug loading range, together with the maturing step of the process of the present invention, enables tailoring of the day 1 "burst" effect as desired.

[0013] The maturing step of the process of the present invention also enables a device whose release rate characteristics are substantially independent of shelf life. By "substantially independent of shelf life" is meant a release profile which is substantially constant during storage up to the assigned expiry date, i.e., over the assigned storage period.

[0014] There is no teaching in the scientific or patent literature as to how altering a drug loading of greater than or equal to ; or less than ; 30% (w/w) for drugs of varying solubility in the polymer matrix itself, affects the release rate characteristics of a matrix device, despite the advantages that might ensue from knowing how to modify release profiled from such a device. Specifically, increasing the drug loading above 30%(w/w), with respect to the total weight of the polymer matrix and subjecting the polymer matrix to maturing, reduces day 1 release rates following insertion of the device into the vaginal space of a user, from a device of matrix design. This effect is more marked with increasing solubility of the drug in the polymer matrix. Without wishing to be bound by theory, it is believed that the drug loading affects the rate of curing. This has the effect of tightening the otherwise loose structure of the cured polymer matrix.

[0015] Alternatively, reducing the drug loading below 30% (w/w) and subjecting the polymer matrix to maturing, increases day 1 release rates following insertion of the device into the vaginal space of a user, from a device of matrix design. This effect is more marked with reducing solubility of the drug in the polymer matrix. Without wishing to be bound by theory, it is believed that the maturing step, by raising the temperature and time, forces the drug towards the surface of the device.

[0016] Advantageously, the curing step is carried out under temperature and time conditions sufficient to produce a polymer matrix that is shape-retaining, i.e., can be removed from a mould. If the elastomer is silicone, and this is preferred, the curing step should be carried out at either 50-100°C, preferably at 60-90°C, for 1 - 10 minutes, preferably for 1.5 to 4 minutes, or, alternatively, at room temperature (15-25°C) for 1 - 24 hours.

[0017] Advantageously, the maturing step is carried out under temperature and time conditions sufficient to alter the release rate characteristics of the device. Specifically, the maturing step can adjust at least the "burst" effect on day 1, depending on, primarily, the drug loading (% w/w) in the device and, secondarily, on the solubility of the drug in the polymer matrix itself.

[0018] The maturing step can also adjust at least the rate of drug release, post-day 1 (referred to hereinafter as the "maintenance" release rate), depending on the drug loading (% w/w) in the device. More specifically, if the drug loading is less than 30%(w/w), a marked increase in the "burst" effect on day 1 is observed together with a subsequent maintenance release (i.e., release on day 2 and subsequent days) increase. If the drug loading is greater than 30% (w/w), a decrease in the "burst" effect on day 1 is observed, this effect being more marked with increasing solubility of the drug in the polymer matrix.

[0019] If the elastomer is silicone, the maturing step can be carried out at 40 - 100°C, preferably 50 - 80°C, for 2 to 72 hours, preferably 12-30 hours, more preferably 16-24 hours.

[0020] Optionally, the process of the invention includes the further step of aging the matured polymer matrix. The aging step can be carried out at 15-30°C, optionally at room temperature (15-25°C), for 5-40 days.

[0021] The maturing step or the maturing and aging steps serve, unexpectedly, to produce a device whose release characteristics are substantially independent of shelf life.

[0022] Before the maturing or the maturing and aging steps, the polymer matrix may, if desired, be housed in an individual pouch.

[0023] A second aspect of the invention is directed to an intravaginal drug delivery device whenever prepared by the process of the first aspect of the present invention. Such a device of the present invention provides a means of intravaginal

drug delivery in a convenient and high compliance manner with a preferred dosing strategy. Specifically, a drug loading in the range 30% to 60% (w/w), with respect to the total weight of the polymer matrix, enables a decreased day 1 release rate following insertion into the vaginal space of a user, from a device of matrix design, whilst a drug loading in the range 5% to 30% (w/w), with respect to the total weight of the polymer matrix, enables an increased day 1 release rate, together with an increased release, post day 1, i.e., an increased maintenance release rate.

[0024] It is within the ordinary skill of the skilled man to determine appropriate conditions for the maturing and aging steps, for any elastomer disclosed hereinafter.

[0025] The amount of therapeutic agent(s) included in the polymer matrix is/are selected to provide the desired therapeutic agent(s) release characteristics.

[0026] The mix of the at least one therapeutic agent with the at least one biocompatible elastomeric polymer may include a crosslinking agent and, optionally, a catalyst.

[0027] The mix of the at least one therapeutic agent with the at least one biocompatible elastomeric polymer may include a release enhancing excipient and, optionally, a crosslinking agent and, further optionally, a catalyst.

[0028] The invention provides a method for increasing day 1 release of at least one therapeutic agent from an intravaginal matrix drug delivery device during the first day following insertion of the device into the vaginal space of a user, the method comprising preparing a device in which less than 30% (w/w) of the at least one therapeutic agent is used to form the mix and, preferably, the at least one therapeutic agent has a solubility in silicone oil at 25°C of less than 0.1 mg/ml; and inserting the device in the vaginal space of the user. The invention also provides use of less than 30% (w/w) of the at least one therapeutic agent in the mix and, preferably, use of at least one therapeutic agent having a solubility in silicone oil at 25°C of less than 0.1 mg/ml, to increase day 1 release of the at least one therapeutic agent from an intravaginal matrix drug delivery device.

[0029] The invention further provides a method for decreasing release of at least one therapeutic agent from an intravaginal matrix drug delivery device during the first day following insertion of the device into the vaginal space of a user, the method comprising preparing a device in which greater than or equal to 30% (w/w) of the at least one therapeutic agent is used to form the mix and, preferably, the at least one therapeutic agent has a solubility in silicone oil at 25°C of greater than or equal to 0.1 mg/ml; and inserting the device in the vaginal space of the user. The invention also provides use of greater than or equal to 30% (w/w) of the at least one therapeutic agent in the mix and, preferably, use of at least one therapeutic agent having a solubility in silicone oil at 25°C of greater than or equal to 0.1 mg/ml, to decrease day 1 release of the at least one therapeutic agent from an intravaginal matrix drug delivery device.

DETAILED DESCRIPTION OF THE INVENTION

[0030] The present invention primarily concerns itself with intravaginal delivery of at least one therapeutic agent into the vaginal space of a user.

[0031] The term "therapeutic agent" is intended to embrace any agent used in the prophylaxis or therapy of any condition affecting the health of the human or animal species.

[0032] The at least one therapeutic agent is generally present in the device of this invention in an amount from about 5 to about 60 w/w% preferably from about 7.5 to about 50 w/w%, and most preferably about 10 to about 40 w/w%, by weight of the polymer matrix. However, the amount of therapeutic agent may clearly be varied depending on, for example, the desired dosing level, the particular therapeutic agent, the release rate effect of excipients used in the device, and the particular elastomeric system employed.

[0033] The term "elastomer" is intended to mean an amorphous high polymer (or mixture thereof) above its/their glass transition temperature. Elastomers can be stretched and retracted rapidly; exhibit high strength and modulus when stretched; and recover fully when the stress is removed. The term "elastomer" includes covalently-linked elastomers, in which the polymer(s) is/are permanently crosslinked to restrain gross mobility, and thermoplastic elastomers, in which the polymer(s) is/are reversibly crosslinked to restrain gross mobility.

[0034] Examples of suitable biocompatible elastomers include, but are not limited to, silicones (organo polysiloxanes including dimethylpolysiloxanes), polyethylene-co-poly (vinyl acetate), styrene-butadiene-styrene block copolymers, polyphosphazenes, poly(isoprene), poly (isobutylene), polybutadienes, polyurethanes, nitrile rubbers, neoprene rubbers or mixtures thereof. Silicones are particularly preferred.

[0035] Preferred elastomers include hydroxyl-terminated organopolysiloxanes (such as polydimethylsiloxanes) of the RTV (room temperature vulcanising) type, which harden to elastomers at room temperature or higher, following the addition of cross-linking agents in the presence of curing catalysts. Suitable cross-linking agents and curing catalysts are well known in the art. A typical curing catalyst would be stannous octoate. Curing temperatures and times will vary, depending on the particular elastomer(s) used. For example, the curing temperature may vary between room temperature (15-25°C) and 150°C but is preferably within the range 50-100°C, optionally 60-90°C. The curing time may vary between a few seconds and up to 24 hours, depending on the elastomer(s) used and the curing temperature chosen.

[0036] Other suitable elastomers include two-component dimethylpolysiloxane compositions using platinum as the

curing catalyst and at a curing temperature of from room temperature to an elevated temperature.

[0037] Intravaginal elastomer drug delivery devices of the present invention may have any shape and be of any dimensions compatible with intravaginal administration to the human female or other animal. With the requirements imposed by drug delivery kinetics, a particularly preferred intravaginal drug delivery device according to the present invention is a ring. Such a ring can be self-inserted high into the vagina, where it is held in place due to its shape and inherent elasticity. More preferred is a drug delivery device in the form of a ring, in which the elastomer is silicone.

[0038] Advantageously, the intravaginal drug delivery device may contain one or more other pharmaceutically compatible agents. Such agents include other therapeutic (pharmacologically active) agents, as well as, pharmacologically inactive agents known in the art as pharmaceutical excipients. By "pharmaceutically compatible, pharmacologically inactive" agent, is meant any agent not intended for use in the prophylaxis or therapy of any condition affecting the health of the human or animal species. Examples of other therapeutic (pharmacologically active) agents that may be advantageous include, but are not limited to, a local anaesthetic such as lidocaine or a local analgesic or a mixture thereof. Examples of pharmacologically inactive agents that may be advantageous include, but are not limited to, hydrophilic compounds that enhance the rate of release of the at least one therapeutic agent from the device, for example, polymers such as povidone or polyvinylpyrrolidone (PVP); modified cellulose ethers, such as hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; microcrystalline cellulose, polyacrylic acid, carbomers, alginic acid, carageenan, cyclodextrins, dextrin, guar gum, gelatin, xanthan gum, lactose, isopropyl myristate and other fatty acid esters; and agents such as sugars. When employed, the release rate enhancing excipient is generally present in an amount of about 0.5 to about 40 w/w%, preferably about 2.5 to about 20 w/w% and more preferably about 2.5 to about 15 w/w%, by weight of the polymer matrix.

[0039] The effect of maturing step or, alternatively, the maturing and aging steps on release rate profile is dependent on physico-chemical drug properties i.e. solubility in the polymer matrix itself; and drug concentration (loading).

[0040] For example, for a relatively low drug loading of less than 30% (w/w), for example, about 10 or 20% w/w, maturing, or maturing and aging, of a matrix device comprising at least one therapeutic agent, not being of "high" solubility, will increase the magnitude of Day 1 release. This effect is more pronounced for a drug of higher solubility, not being of "high" solubility as defined below, in the polymer matrix.

[0041] For a relatively high drug loading of greater than 30% (w/w) (e.g., about 35-40% w/w), maturing or maturing and aging will decrease the magnitude of Day 1 release. This effect is more pronounced for a drug of lower solubility in the polymer matrix.

[0042] By "relatively low" drug loading, is meant a drug loading of less than 30% (w/w), optionally less than 25% (w/w) or even less than about 20% (w/w), perhaps in the range of 10-20% (w/w), all by total weight of the mix.

[0043] By "relatively high" drug loading, is meant a drug loading of greater than 30% (w/w), optionally greater than about 35% (w/w), perhaps in the range of 35-40% (w/w), all by total weight of the mix.

[0044] For a drug of high solubility in the polymer matrix, at a drug loading of 30% (w/w) or less, maturing, or maturing and aging, will have no observable effect on day 1 release. By "high solubility" where the polymer matrix is silicone, is meant a solubility in liquid silicone at 25°C of 0.24mg/nml or-greater. The skilled man will appreciate that, if the polymer matrix is changed, the definition of "high solubility" would need to be assessed in that particular polymer matrix.

[0045] By "higher solubility" is meant, a solubility in silicone oil at 25°C of greater than 0.1 mg/ml, but less than 0.24 mg/ml. Thus, the solubilities of testosterone and terconazole in silicone oil at 25°C are 0.14 mg/ml and 0.20 mg/ml, respectively.

[0046] By "low solubility" is meant a solubility in silicone oil at 25°C of less than 0.1 mg/ml. Thus, the solubility of metronidazole and acyclovir are 0.006 mg/ml and < 0.08 mg/ml, respectively, in silicone oil at 25°C.

[0047] Although a matrix device usually shows first order release decay, the "maintenance" rate of drug release, following the initial 24 hour period, can be adapted to "appear" substantially linear if the diffusional distance that the drug must travel from the receding drug boundary to the outer surface of the device is as small as possible. This, in effect, means that a drug loading of less than 30% (w/w) can be employed, together with the above-mentioned maturing conditions, to encourage migration of the drug towards the periphery of the device. This enhanced migration effect is more pronounced for drugs of low solubility. Alternatively, a drug loading of greater than 30% can be employed, together with the maturing conditions, to tighten the structure of the device. This, in turn, inhibits migration of the drug towards the periphery of the device, an effect which is more pronounced for drugs of higher solubility.

[0048] The geometry of the ring (where the device is a ring) also plays a role in achieving the desired drug release characteristics - in the present context, the term "geometric" encompasses the overall diameter of the ring and its cross-sectional diameter.

[0049] The particle size of the at least one therapeutic agent may be varied to alter the release rate characteristics of the device of this invention, in the form of a matrix design device.

[0050] An embodiment of the invention will now be described by reference to the following example 5. It should be understood that this embodiment is disclosed solely by way of further illustrating the invention and should not be taken in any way to limit the scope of said invention as defined by the claims.

General Method of Manufacture

[0051] An intravaginal drug delivery device according to the present invention can be prepared by blending 94.24 parts by weight of a hydrophobic elastomeric polymer (polydimethylsiloxane) containing about 10% w/w diatomaceous earth as the filler, with 5.76 parts by weight of a cross-linking agent, n-propylorthosilicate, to form an elastomer mix. One suitable hydrophobic elastomeric polymer is stannous octoate-cured polydimethylsiloxane polymer, a suitable example of which is Dow Coming 382. The appropriate amount of the at least one therapeutic agent was then added, to form a mix. Optionally, additional pharmacologically active agents or pharmaceutical excipients can be included at this stage by similarly blending them into the mix - thus, the rings of Examples 2 and 5 each contain 10% (w/w) of a pharmaceutical excipient, namely, isopropyl myristate and lactose, respectively. Prior to injection moulding or extrusion, the drug-containing mix was activated by blending 140 parts by weight of this mix with 1 part by weight of a catalyst, for example, stannous octoate. The resultant final active mix is injected into a suitable mould and cured. The mould is then opened, following which the device is removed and trimmed.

[0052] The geometric characteristics of the device can be varied as required by the use of appropriately sized moulds or extrusion nozzles, as will be obvious to those skilled in the art.

Example 1- Metronidazole (does not form part of the claimed invention)

[0053] The metronidazole used had a particle size distribution in which 90% is less than 90 μ m and 50% is less than 20 μ m. The appropriate amount of metronidazole, which was added to the aforementioned elastomer mix, was 40% (w/w), by weight of the final manufactured device. This active mix is injected into a suitable mould (cross-sectional diameter=9.5mm, outer diameter=56mm) and cured at 90°C for 4 minutes. The resultant matrix intravaginal drug delivery device has a ring geometry of 9.2mm (cross-sectional diameter) and 54 mm (outer diameter). The ring is subjected to a maturing step at 60°C for 16 hours, followed by, optionally, an aging step in an individual pouch, specifically, subsequent storage at ambient temperature (15 - 25°C), to improve the mechanical and release characteristics.

In Vitro Drug Release: Example 1

[0054] These release rates were determined in 0.9% (w/v) saline. Each ring was suspended in saline, in a volume of 500ml for day 1 and in 250 ml for each of the subsequent days. The flasks were maintained at 37°C in a shaking incubator, the saline being refreshed every 24 hours.

[0055] Typical in vitro release rates are shown below, both for a control ring with no maturing or aging step (n=6); for a ring of the present invention with maturing at 60°C for 16 hours (n=12); and for a ring (n=3) of the present invention with maturing at 60°C for 16 hours followed by aging (storage, in individual pouches, at a controlled temperature of 25°C and at 60% relative humidity) for 3 weeks:

Day	No maturing or aging	Matured at 60°C/16hrs	Matured at 60 °C/16hrs and aged (stored at the controlled temperature for 3 weeks)
Mean (% R.S.D.) Drug release rate (mg/day)			
1	82.9 (4.0)	74.4 (3.4)	70.5 (0.4)
2	42.0 (2.3)	42.3 (3.8)	48.6 (2.3)
3	31.5 (3.2)	33.6 (3.9)	37.2 (1.6)
4	24.2 (2.9)	28.5 (3.9)	33.1 (3.6)
5	21.2 (5.7)	24.4 (3.3)	30.1 (1.7)
Mean of 2-5	29.7	32.2	37.3

[0056] These data suggest that the maturing step and the optional aging step serve to alter the release rate characteristics of the intravaginal drug delivery device.

Specifically, the release rate on day 1, or "burst" effect, is reduced to 89.7% and 85.0%, respectively (relative to the control), whilst the maintenance release rate (mean of days 2 - 5), post-day 1, is increased to 108.4% and 125.6%, respectively (again relative to the control).

Example 2 - Terconazole (does not form part of the claimed invention)

[0057] The terconazole used had a particle size distribution of which 100% is less than 10 μ m. The appropriate amount

of terconazole, which was added to the aforementioned elastomer mix, was 37% (w/w), by weight of the final manufactured device. This active mix is injected into a suitable mould (cross-sectional diameter=9.5mm, outer diameter=56mm) and cured at 60°C for 1.5 minutes. The resultant matrix intravaginal drug delivery device has a ring geometry of 9.2mm (cross-sectional diameter) and 54 mm (outer diameter). The ring is subjected to a maturing step at 50°C or 60°C for 24 hours.

In Vitro Drug Release: Example 2

[0058] These release rates were determined in 0.9% (w/v) saline. Each ring was suspended in saline, in a volume of 2000ml for day 1 and in 1000 ml for each of the subsequent days. The flasks were maintained at 37°C in a shaking incubator, the saline being refreshed every 24 hours.

[0059] Typical in vitro release rates are shown below, both for a control ring with no maturing step (n=3); for a ring of the present invention with maturing at 50°C for 24 hours (n=3); and for a ring (n=3) of the present invention with maturing at 60°C for 24 hours - all rings were tested within one hour of completion of the maturing step:

Day	No maturing	Matured at 50°C/24hrs	Matured at 60°C/24hrs
	Mean (% R.S.D.) Drug release rate (mg/day)		
1	94.6 (1.6)	46.6 (2.5)	47.0 (3.5)
2	23.1 (4.3)	19.7 (6.2)	18.9 (2.7)
3	14.4 (10.3)	14.5 (2.4)	14.4 (4.6)
4	12.3 (3.7)	11.4 (1.5)	11.5 (2.6)
5	14.9 (2.1)	12.5 (2.5)	12.1 (2.2)
Mean of 2-5	16.2	14.5	14.2

[0060] These data suggest that the maturing step serves to alter the release rate characteristics of the intravaginal drug delivery device. Specifically, the release rate on day 1, or "burst" effect, is reduced to 49.3% and 49.7%, respectively (relative to the control), whilst the maintenance release rate (mean of days 2 - 5), post-day 1, is slightly decreased to 89.5% and 87.7%, respectively (again relative to the control). In addition, there is no statistical difference between maturing at 50°C and at 60°C, each for 24 hours.

Example 3 - Testosterone (does not form part of the claimed invention)

[0061] The testosterone used had a particle size distribution of 100% less than 15µm. The appropriate amount of testosterone, which was added to the aforementioned elastomer mix, was 10% (w/w), by weight of the final manufactured device. This active mix is injected into a suitable mould (cross-sectional diameter=9.5mm, outer diameter=56mm) and cured at 80°C for 2 minutes. The resultant matrix intravaginal drug delivery device has a ring geometry of 9.2mm (cross-sectional diameter) and 54 mm (outer diameter). The ring is subjected to a maturing step at 50°C or 80°C for 24 hours.

In Vitro Drug Release: Example 3

[0062] These release rates were determined in 0.3% (w/v) sodium lauryl sulphate (SLS). Each ring was suspended in SLS, in a volume of 2500ml for day 1 and in 1000ml for each of the subsequent days. The flasks were maintained at 37°C in a shaking incubator, the medium being refreshed every 24 hours.

[0063] Typical in vitro release rates are shown below, both for a control ring with no maturing step (n=3); for a ring of the present invention with maturing at 50°C for 24 hours (n=3); and for a ring (n=3) of the present invention with maturing at 80°C for 24 hours - all rings were tested one hour of completion of the maturing step:

Day	No maturing	Matured at 50°C/24hrs	Matured at 80°C/24hrs
	Mean (% R.S.D.) Drug release rate (mg/day)		
1	39.6 (0.9)	44.3 (0.4)	43.8 (0.4)
2	17.5 (0.4)	22.3 (1.0)	21.7 (0.5)
3	12.5 (1.3)	16.9 (0.4)	16.5 (1.8)
4	10.2 (1.6)	14.0 (0.2)	13.7 (0.8)
5	8.7 (1.1)	12.1 (0.6)	11.8 (1.0)

(continued)

Day	No maturing	Matured at 50°C/24hrs	Matured at 80°C/24hrs
	Mean (% R.S.D.) Drug release rate (mg/day)		
Mean of 2-5	12.2	16.3	15.9

[0064] These data suggest that the maturing step alters the release rate characteristics of the intravaginal drug delivery device. Specifically, the release rate on day 1, or "burst" effect, is increased by 111.9% and 110.6%, respectively (relative to the control), whilst the maintenance release rate (mean of days 2 - 5), post-day 1, is slightly increased to 133.6% and 130.3%, respectively (again relative to the control). In addition, there is no statistical difference between maturing at 50°C and at 80°C, each for 24 hours on either day 1 release, or maintenance release.

Example 4 - Estradiol-3-Acetate (does not form part of the claimed invention)

[0065] The estradiol-3-acetate used had a particle size distribution of 99% less than 16µm. The appropriate amount of estradiol-3-acetate, which was added to the aforementioned elastomer mix, was 10% (w/w), by weight of the final manufactured device. This active mix is injected into a suitable mould (cross-sectional diameter=9.5mm, outer diameter=56mm) and cured at 80°C for 2 minutes. The resultant matrix intravaginal drug delivery device has a ring geometry of 9.2mm (cross-sectional diameter) and 54 mm (outer diameter). The ring is subjected to a maturing step at 50°C or 80°C for 24 hours.

In Vitro Drug Release: Example 4

[0066] These release rates were determined in 0.3% (w/v) SLS. Each ring was suspended in SLS, in a volume of 2000 ml for day 1 and in 1000 ml for each of the subsequent days. The flasks were maintained at 37°C in a shaking incubator, the medium being refreshed every 24 hours.

[0067] Typical in vitro release rates are shown below, both for a control ring with no maturing step (n=3); for a ring of the present invention with maturing at 50°C for 24 hours (n=3); and for a ring (n=3) of the present invention with maturing at 80°C for 24 hours - all rings were tested one hour of completion of the maturing step:

Day	No maturing	Matured at 50 °C/24hrs	Matured at 80 °C/24hrs
	Mean (% R.S.D.) Drug release rate (mg/day)		
1	45 (3.7)	42 (2.6)	39.4 (0.6)
2	19.3 (4.7)	20.0 (1.0)	19.3 (1.2)

[0068] These data suggest that, for a drug of high solubility, and a relatively low drug loading, there is no significant alteration in day 1 release rate.

Example 5 - Acyclovir

[0069] The acyclovir used had a particle size distribution of which 100% is less than 24 µm. The appropriate amount of acyclovir, which was added to the aforementioned elastomer mix, was 20% (w/w), by weight of the final manufactured device. This active mix is injected into a suitable mould (cross-sectional diameter=9.5mm, outer diameter=56mm) and cured at 60°C for 1.5 minutes. The resultant matrix intravaginal drug delivery device has a ring geometry of 9.2mm (cross-sectional diameter) and 54 mm (outer diameter). The ring is subjected to a maturing step at 50°C or 60°C for 24 hours.

In Vitro Drug Release: Example 5

[0070] These release rates were determined in 0.9% (w/v) saline. Each ring was suspended in saline, in a volume of 2000ml for day 1 and in 1000 ml for each of the subsequent days. The flasks were maintained at 37°C in a shaking incubator, the saline being refreshed every 24 hours.

[0071] Typical in vitro release rates are shown below, both for a control ring with no maturing step (n=3); for a ring of the present invention with maturing at 50°C for 24 hours (n=3); and for a ring (n=3) of the present invention with maturing at 60°C for 24 hours - all rings were tested within one hour of completion of the maturing step:

Day	No maturing	Matured at 50°C/24hrs	Matured at 60°C/24hrs)
	Mean (% R.S.D.) Drug release rate (µg/day)		
1	2595.2 (8.9)	5660.3 (4.2)	5775.4 (9.9)
2	573.5 (2.8)	1189.7 (15.0)	1395.8 (19.0)
3	361.9 (3.2)	786.5 (18.1)	947.5 (17.2)
4	285.3 (11.4)		
5	283.6 (2.8)		
Mean of 2-3	467.7	988.1	1171.7

[0072] These data suggest that the maturing step alters the release rate characteristics of the intravaginal drug delivery device. Specifically, the release rate on day 1, or "burst" effect, is increased to 218.1% and 222.5%, respectively (relative to the control), whilst the maintenance release rate (mean of days 2 and 3), post-day 1, is also increased to 211.3% and 250.5%, respectively (again relative to the control). There is, therefore, a further difference between maturing at 50°C and at 60°C, each for 24 hours.

Claims

- A method for altering the release characteristics of an intravaginal matrix drug delivery device, the method comprising preparing the drug delivery device by a process comprising the steps of:
 - combining less than 30% (w/w) of at least one therapeutic agent with at least one biocompatible elastomeric polymer, and in which the at least one biocompatible elastomeric polymer is silicone and the at least one therapeutic agent has a solubility in silicone oil at 25°C of less than 0.1 mg/ml, to form a mix for preparing a drug delivery device having increased day 1 release rates;
 - curing said mix to form a polymer matrix, in which the biocompatible elastomeric polymer is silicone and either the curing step is carried out at 50-100°C for 1-10 minutes, optionally for 1.5 to 5 minutes, or the curing step is carried out at 15-25°C for 1-24 hours; and
 - maturing said shape-retaining polymer matrix under temperature and time conditions sufficient to form the intravaginal drug delivery device, in which said maturing step is carried out at 40-100°C for 2-72 hours.
- A method according to Claim 1, in which the curing step is carried out at 60-90°C, for 1-10 minutes, optionally for 1.5 to 5 minutes.
- A method according to Claim 1, in which the maturing step is carried at 40-100°C for 12-30 hours, preferably 16-24 hours.
- A method according to any one of Claims 1 or 3, in which the maturing step is carried at 50-80°C for 2-72 hours, preferably 12-30 hours, more preferably 16-24 hours.
- A method according to any one of Claims 1 or 3 or 4, in which the maturing step is carried out to produce a device whose release characteristics are substantially independent of shelf life.
- A method according to any one of the preceding claims, in which the process additionally comprises a step of aging the matured polymer matrix.
- A method according to Claim 6, in which the aging step is carried out at 15-30°C, preferably 15-25°C, for 5-40 days.
- A method according to Claim 6 or 7 when dependent on any one of Claims 1 to 5, in which the maturing step and the aging step are carried out to produce a device whose release characteristics are substantially independent of shelf life.

Patentansprüche

1. Verfahren zur Veränderung der Freisetzungseigenschaften einer intravaginalen Matrix-Vorrichtung zur Arzneimittelabgabe, wobei das Verfahren die Herstellung der Arzneimittelabgabevorrichtung durch einen Prozess umfasst, der die folgenden Schritte umfasst:

(i) Vereinigen von weniger als 30 % (m/m) von mindestens einem Therapeutikum mit mindestens einem biologisch verträglichen elastomeren Polymer, und in welchem das mindestens eine biologisch verträgliche elastomere Polymer Silikon ist und das mindestens eine Therapeutikum eine Löslichkeit in Silikonöl bei 25 °C von kleiner als 0,1 mg/ml aufweist, um eine Mischung zur Herstellung einer Arzneimittelabgabevorrichtung zu bilden, die erhöhte Freisetzungsraten am Tag 1 aufweist;

(ii) Aushärten der Mischung, um eine Polymermatrix zu bilden, in der das biologisch verträgliche elastomere Polymer Silikon ist und entweder der Aushärtungsschritt bei 50-100 °C für 1-10 Minuten, optional für 1,5 bis 5 Minuten durchgeführt wird oder der Aushärtungsschritt bei 15-25 °C für 1-24 Stunden durchgeführt wird; und

(iii) Reifen der formbeständigen Polymermatrix unter hinreichenden Temperatur- und Zeitbedingungen, um die intravaginale Arzneimittelabgabevorrichtung zu bilden, in der der Reifungsschritt bei 40-100 °C für 2-72 Stunden durchgeführt wird.

2. Verfahren nach Anspruch 1, in dem der Aushärtungsschritt bei 60-90 °C für 1-10 Minuten, optional für 1,5 bis 5 Minuten durchgeführt wird.

3. Verfahren nach Anspruch 1, in dem der Reifungsschritt bei 40-100 °C für 12-30 Stunden, bevorzugt 16-24 Stunden durchgeführt wird.

4. Verfahren nach einem der Ansprüche 1 oder 3, in dem der Reifungsschritt bei 50-80 °C für 2-72 Stunden, bevorzugt 12-30 Stunden, bevorzugter 16-24 Stunden durchgeführt wird.

5. Verfahren nach einem der Ansprüche 1 oder 3 oder 4, in dem der Reifungsschritt durchgeführt wird, um eine Vorrichtung zu erzeugen, deren Freisetzungseigenschaften im Wesentlichen unabhängig von der Haltbarkeitsdauer sind.

6. Verfahren nach einem der vorstehenden Ansprüche, in dem der Prozess zusätzlich einen Schritt der Alterung der gereiften Polymermatrix umfasst.

7. Verfahren nach Anspruch 6, in dem der Alterungsschritt bei 15-30 °C, bevorzugt 15-25 °C für 5-40 Tage durchgeführt wird.

8. Verfahren nach Anspruch 6 oder 7, wenn abhängig von einem der Ansprüche 1 bis 5, in dem der Reifungsschritt und der Alterungsschritt durchgeführt werden, um eine Vorrichtung zu erzeugen, deren Freisetzungseigenschaften im Wesentlichen unabhängig von der Haltbarkeitsdauer sind.

Revendications

1. Méthode de modification des caractéristiques de libération d'un dispositif d'administration de médicament en matrice intravaginale, la méthode comprenant la préparation du dispositif d'administration de médicament par un procédé comprenant les étapes consistant à :

(i) combiner moins de 30% (p/p) d'au moins un agent thérapeutique avec au moins un polymère élastomère biocompatible, et où le au moins un polymère élastomère biocompatible est de la silicone et le au moins un agent thérapeutique possède une solubilité dans de l'huile de silicone à 25°C inférieure à 0,1 mg/ml, afin de former un mélange pour préparer un dispositif d'administration de médicament ayant des taux de libération accrus le jour 1 ;

(ii) faire durcir ledit mélange afin de former une matrice polymère, où le polymère élastomère biocompatible est de la silicone et l'étape de durcissement est effectuée à 50-100°C pendant 1-10 minutes, éventuellement pendant de 1,5 à 5 minutes, ou bien l'étape de durcissement est effectuée à 15-25°C pendant 1-24 heures ; et

(iii) faire mûrir ladite matrice polymère à conservation de forme dans des conditions de température et de temps suffisantes pour former le dispositif d'administration de médicament intravaginal, où ladite étape de

maturation est effectuée à 40-100°C pendant 2-72 heures.

2. Méthode selon la revendication 1, dans laquelle l'étape de durcissement est effectuée à 60-90°C, pendant 1-10 minutes, éventuellement pendant de 1,5 à 5 minutes.
3. Méthode selon la revendication 1, dans laquelle l'étape de maturation est effectuée à 40-100°C pendant 12-30 heures, préférentiellement 16-24 heures.
4. Méthode selon l'une quelconque des revendications 1 ou 3, dans laquelle l'étape de maturation est effectuée à 50-80°C pendant 2-72 heures, préférentiellement 12-30 heures, plus préférentiellement 16-24 heures.
5. Méthode selon l'une quelconque des revendications 1 ou 3 ou 4, dans laquelle l'étape de maturation est effectuée afin de produire un dispositif dont les caractéristiques de libération sont sensiblement indépendantes de la durée de conservation.
6. Méthode selon l'une quelconque des revendications précédentes, dans laquelle le procédé comprend en outre une étape de vieillissement de la matrice polymère maturée.
7. Méthode selon la revendication 6, dans laquelle l'étape de vieillissement est effectuée à 15-30°C, préférentiellement 15-25°C, pendant 5-40 jours.
8. Méthode selon la revendication 6 ou 7 lorsque dépendante de l'une quelconque des revendications 1 à 5, dans laquelle l'étape de maturation et l'étape de vieillissement sont effectuées afin de produire un dispositif dont les caractéristiques de libération sont sensiblement indépendantes de la durée de conservation.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4155991 A [0003]
- US 5188835 A [0004]
- US 4012497 A [0005]
- US 6103256 A [0006]

Non-patent literature cited in the description

- **JACKANICZ, T. M.** Vaginal Contraception: New Developments. *Harper and Row*, 1979, 201-212 [0002]